Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws

Clinical Chemistry

Volumn 59, Issue 3, 2013, Pages 519-526

  Bergamaschi, Mateus M ^a,b,c   Karschner, Erin L ^a   Goodwin, Robert S ^a   Scheidweiler, Karl B ^a   Hirvonen, Jussi ^c   Queiroz, Regina H C ^b   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; TETRAHYDROCANNABINOL;

ADSORPTION; ADULT; ARTICLE; BLOOD SAMPLING; CANNABIS SMOKING; CAR DRIVING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ADSORPTION; DRUG BLOOD LEVEL; DRUG EXCRETION; HUMAN; MALE; SAMPLING;

EID: 84874593197     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.195503     Document Type: Article

References (40)

1. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2011; New York, 2011;272.
2. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2010 National Survey on Drug Use and Health: summary of national findings. Rockville (MD): SAMHSA; 2011. NSDUH Series H-41, HHS publ. no. (SMA) 11-4658.
3. Elkashef A, Vocci F, Huestis M, Haney M, Budney A, Gruber A, el-Guebaly N. Marijuana neurobiology and treatment. Subst Abus 2008;29:17-29.
4. Ramaekers J, Kauert G, Theunissen E, Toennes S, Moeller M. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol 2009;23:266-77.
5. Lane SD, Cherek DR, Tcheremissine OV, Lieving LM, Pietras CJ. Acute marijuana effects on human risk taking. Neuropsychopharmacology 2005;30: 800-9.
6. Vandrey R, Haney M. Pharmacotherapy for cannabis dependence: how close are we? CNS Drugs 2009;23:543-53.
7. Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Frank RA. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 2001;58:322-30.
8. Eldreth DA, Matochik JA, Cadet JL, Bolla KI. Abnormal brain activity in prefrontal brain regions in abstinent marijuana users. NeuroImage 2004;23:914-20.
9. Pope H, Gruber A, Hudson J, Huestis M, Yurgelun-Todd D. Neuropsychological performance in longterm cannabis users. Arch Gen Psychiatry 2001; 58:909-15.
10. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects of marijuana use. Neurology 2002;59:1337-43.
11. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2009 National Survey on Drug Use and Health: volume I. Summary of national findings. Rockville (MD): SAMHSA; 2010. Office of Applied Studies, NSDUH Series H-38A, DHHS publ. no. (SMA) 10-4586.
12. Lacey JH, Kelley-Baker T, Furr-Holden D, Voas RB, Romano E, Ramirez A, et al. (Pacific Institute for Research and Evaluation, Calverton, MD). 2007 National Roadside Survey of Alcohol and Drug Use by Drivers: drug results. Washington (DC): National Highway Traffic Safety Administration; 2009. Report No. DOT HS 811 249: Contract No. DTNH22-06-C-00040.
13. Compton R, Berning A. Results of the 2007 National Roadside Survey of Alcohol and Drug Use by Drivers. Washington (DC): National Highway Traffic Safety Administration; 2009. Traffic Safety Facts; DOT HS 811 175.
14. Jones RK, Shinar D, Walsh JM (Mid-America Research Institute, Winchester, MA). State of knowledge of drug-impaired driving. Washington (DC): National Highway Traffic Safety Administration; 2003. Report No. DOT HS 809 642; Contract or Grant No. DTNH22-98-D-25079.
15. Blows S, Ivers RQ, Connor J, Ameratunga S, Woodward M, Norton R. Marijuana use and car crash injury. Addiction 2005;100:605-11.
16. Drummer OH, Gerostamoulos J, Batziris H, Chu M, Caplehorn J, Robertson MD, Swann P. The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. Accid Anal Prev 2004;36:239-48.
17. Laumon B, Gadegbeku B, Martin JL, Biecheler MB. Cannabis intoxication and fatal road crashes in France: population based case-control study. BMJ 2005;331:1371.
18. Ramaekers JG, Moeller MR, van Ruitenbeek P, Theunissen EL, Schneider E, Kauert G. Cognition and motor control as a function of Delta9-THC concentration in serum and oral fluid: limits of impairment. Drug Alcohol Depend 2006;85:114-22.
19. Lacey J, Brainard K, Snitow S (Pacific Institute for Research and Evaluation, Calverton, MD). Drug per se laws: a review of their use in states. Washington (DC): National Highway Traffic Safety Administration; 2010. Report No. DOT HS 811 317; Contract or Grant No. DTNH22-02-D-95121 Task #13.
20. Verstraete A, Knoche A, Jantos R, Skopp G, Gjerde H, Vindenes V, et al. Per se limits-methods of defining cut-off values for zero tolerance. Deliverable 1.4.2. Driving under the Influence of Drugs, Alcohol and Medicines; 2011. 6th Framework Programme.
21. Johansson E, Agurell S, Hollister LE, Halldin MM. Prolonged apparent half-life of Delta-1-tetrahydrocannabinol in plasma of chronic marijuana users. J Pharm Pharmacol 1988;40:374-5.
22. Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers 2007;4:1770-804.
23. Bornheim LM, Lasker JM, Raucy JL. Human hepatic microsomal metabolism of Delta-1-tetrahydrocannabinol. Drug Metab Dispos 1992; 20:241-6.
24. Mura P, Kintz P, Dumestre V, Raul S, Hauet T. THC can be detected in brain while absent in blood. J Anal Toxicol 2005;29:842-3.
25. Jones AW, Holmgren A, Kugelberg FC. Driving under the influence of cannabis: a 10-year study of age and gender differences in the concentrations of tetrahydrocannabinol in blood. Addiction 2008;103:452-61.
26. Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C, et al. Reversible and regionally selective downregulation of brain cannabinoid CB(1) receptors in chronic daily cannabis smokers. Mol Psychiatry 2012;17:642-9.
27. Fattore L, Fratta W. How important are sex differences in cannabinoid action? Br J Pharmacol 2010;160:544-8.
28. Lowe RH, Karschner EL, Schwilke EW, Barnes AJ, Huestis MA. Simultaneous quantification of Delta-9-tetrahydrocannabinol (THC), 11-hydroxy-Delta-9- tetrahydrocannabinol (11-OH-THC), and 11-nor-Delta-9-tetrahydrocannabinol-9- carboxylic acid (THCCOOH) in human plasma using twodimensional gas chromatography, cryofocusing, and electron impact-mass spectrometry. J Chromatogr A 2007;1163:318-27.
29. Karschner E, Schwilke E, Lowe R, Darwin W, Pope H Jr, Herning R, et al. Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? Addiction 2009;104:2041-8.
30. Johansson E, Noren K, Sjovall J, Halldin MM. Determination of Delta 1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry. Biomed Chromatogr 1989;3:35-8.
31. Brunet B, Doucet C, Venisse N, Hauet T, Hebrard W, Papet Y, et al. Validation of large white pig as an animal model for the study of cannabinoids metabolism: application to the study of THC distribution in tissues. Forens Sci Int 2006;161:169-74.
32. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002;287:1123-31.
33. Ramaekers J, Theunissen E, de Brouwer M, Toennes S, Moeller M, Kauert G. Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users. Psychopharmacology (Berl) 2011;214:391-401.
34. Haney M, Comer SD, Ward AS, Foltin RW, Fischman MW. Factors influencing marijuana selfadministration by humans. Behav Pharmacol 1997;8:101-12.
35. Gorelick DA, Goodwin RS, Schwilke E, Schwope DM, Darwin WD, Kelly DL, et al. Antagonistelicited cannabis withdrawal in humans. J Clin Psychopharmacol 2011;31:603-12.
36. Gonzalez R. Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. Neuropsychol Rev 2007;17: 347-61.
37. Pope HG, Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. JAMA 1996;275:521-7.
38. Grotenhermen F, Leson G, Berghaus G, Drummer OH, Kruger HP, Longo M, et al. Developing limits for driving under cannabis. Addiction 2007;102: 1910-7.
39. Farrell LJ, Kerrigan S, Logan BK. Recommendations for toxicological investigation of drug impaired driving. J Forensic Sci 2007;52:1214-8.
40. Schwope DM, Karschner EL, Gorelick DA, Huestis MA. Identification of recent cannabis use: wholeblood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem 2011;57:1406-14.